Shalini Sharp
2018 - Ultragenyx Pharmaceutical
In 2018, Shalini Sharp earned a total compensation of $2.1M as Chief Financial Officer and Executive Vice President at Ultragenyx Pharmaceutical, a 21% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $198,695 |
|---|---|
| Option Awards | $1,019,820 |
| Salary | $491,369 |
| Stock Awards | $339,010 |
| Other | $32,827 |
| Total | $2,081,721 |
Sharp received $1M in option awards, accounting for 49% of the total pay in 2018.
Sharp also received $198.7K in non-equity incentive plan, $491.4K in salary, $339K in stock awards and $32.8K in other compensation.
Rankings
In 2018, Shalini Sharp's compensation ranked 5,526th out of 14,244 executives tracked by ExecPay. In other words, Sharp earned more than 61.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,526 out of 14,244 | 61st |
Division Manufacturing | 2,085 out of 5,759 | 64th |
Major group Chemicals And Allied Products | 768 out of 2,122 | 64th |
Industry group Drugs | 643 out of 1,811 | 65th |
Industry Pharmaceutical Preparations | 496 out of 1,385 | 64th |
Source: SEC filing on April 22, 2019.
Sharp's colleagues
We found six more compensation records of executives who worked with Shalini Sharp at Ultragenyx Pharmaceutical in 2018.
2018
Wladimir Hogenhuis
Ultragenyx Pharmaceutical
Chief Operating Officer
2018
Camille Bedrosian
Ultragenyx Pharmaceutical
Chief Medical Officer
2018
Emil Kakkis
Ultragenyx Pharmaceutical
Chief Executive Officer
2018
Karah Parschauer
Ultragenyx Pharmaceutical
General Counsel
2018
Thomas Kassberg
Ultragenyx Pharmaceutical
Chief Business Officer and Executive Vice President
2018
John Pinion
Ultragenyx Pharmaceutical